{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:43:20Z","timestamp":1792788200343,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"St. Elisabeth Gruppe GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Radiographic progression and course of inflammation over 2\u00a0years in patients with non-radiographic axial spondyloarthritis (nr-axSpA) from the phase 3, randomized, PREVENT study are reported here.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the PREVENT study, adult patients fulfilling the Assessment of SpondyloArthritis International Society classification criteria for nr-axSpA with elevated CRP and\/or MRI inflammation received secukinumab 150\u00a0mg or placebo. All patients received open-label secukinumab from week 52 onward. Sacroiliac (SI) joint and spinal radiographs were scored using the modified New York (mNY) grading (total sacroiliitis score; range, 0\u20138) and modified Stoke Ankylosing Spondylitis Spine Score (mSASSS; range, 0\u201372), respectively. SI joint bone marrow edema (BME) was assessed using the Berlin Active Inflammatory Lesions Scoring (0\u201324) and spinal MRI using the Berlin modification of the AS spine MRI (ASspiMRI) scoring (0\u201369).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 78.9% (438\/555) of patients completed week 104 of the study. Over 2\u00a0years, minimal changes were observed in total radiographic SI joint scores (mean [SD] change,\u2009\u2212\u20090.04 [0.49] and 0.04 [0.36]) and mSASSS scores (0.04 [0.47] and 0.07 [0.36]) in the secukinumab and placebo-secukinumab groups. Most of the patients showed no structural progression (increase\u2009\u2264\u2009smallest detectable change) in SI joint score (87.7% and 85.6%) and mSASSS score (97.5% and 97.1%) in the secukinumab and placebo-secukinumab groups. Only 3.3% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097) and 2.9% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093) of patients in the secukinumab and placebo-secukinumab groups, respectively, who were mNY-negative at baseline were scored as mNY-positive at week 104. Overall, 1.7% and 3.4% of patients with no syndesmophytes at baseline in the secukinumab and placebo-secukinumab group, respectively, developed\u2009\u2265\u20091 new syndesmophyte over 2\u00a0years. Reduction in SI joint BME observed at week 16 with secukinumab (mean [SD],\u2009\u2212\u20091.23 [2.81] vs\u2009\u2212\u20090.37 [1.90] with placebo) was sustained through week 104 (\u2212\u20091.73 [3.49]). Spinal inflammation on MRI was low at baseline (mean score, 0.82 and 1.07 in the secukinumab and placebo groups, respectively) and remained low (mean score, 0.56 at week 104).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Structural damage was low at baseline and most patients showed no radiographic progression in SI joints and spine over 2\u00a0years in the secukinumab and placebo-secukinumab groups. Secukinumab reduced SI joint inflammation, which was sustained over 2\u00a0years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT02696031.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-023-03051-5","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:02:41Z","timestamp":1684195361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis"],"prefix":"10.1186","volume":"25","author":[{"given":"Juergen","family":"Braun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne S.","family":"Gensler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"van de Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Stefanska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Readie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno B.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"issue":"10089","key":"3051_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73\u201384.","journal-title":"Lancet"},{"issue":"6","key":"3051_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3051_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/14397595.2020.1830512","volume":"31","author":"H Kameda","year":"2021","unstructured":"Kameda H, Kobayashi S, Tamura N, Kadono Y, Tada K, Yamamura M, et al. Non-radiographic axial spondyloarthritis. Mod Rheumatol. 2021;31(2):277\u201382.","journal-title":"Mod Rheumatol"},{"issue":"11","key":"3051_CR4","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1136\/annrheumdis-2019-215707","volume":"78","author":"A Boel","year":"2019","unstructured":"Boel A, Molto A, van der Heijde D, Ciurea A, Dougados M, Gensler LS, et al. Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. Ann Rheum Dis. 2019;78(11):1545\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3051_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361\u20138.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"3051_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.semarthrit.2014.10.009","volume":"44","author":"A Boonen","year":"2015","unstructured":"Boonen A, Sieper J, van der Heijde D, Dougados M, Bukowski JF, Valluri S, et al. The burden of non-radiographic axial spondyloarthritis. Semin Arthritis Rheum. 2015;44(5):556\u201362.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"3051_CR7","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/acr.21688","volume":"64","author":"U Kiltz","year":"2012","unstructured":"Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken). 2012;64(9):1415\u201322.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"3051_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2018.1477591","volume":"14","author":"M Protopopov","year":"2018","unstructured":"Protopopov M, Poddubnyy D. Radiographic progression in non-radiographic axial spondyloarthritis. Expert Rev Clin Immunol. 2018;14(6):525\u201333.","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"3051_CR9","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599\u2013613.","journal-title":"Arthritis Rheumatol"},{"issue":"26","key":"3051_CR10","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348.","journal-title":"N Engl J Med"},{"issue":"2","key":"3051_CR11","doi-asserted-by":"publisher","first-page":"e001005","DOI":"10.1136\/rmdopen-2019-001005","volume":"5","author":"X Baraliakos","year":"2019","unstructured":"Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, et al. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open. 2019;5(2):e001005.","journal-title":"RMD Open"},{"issue":"1","key":"3051_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","volume":"19","author":"K Pavelka","year":"2017","unstructured":"Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19(1):285.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"3051_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/acr2.11102","volume":"2","author":"K Pavelka","year":"2020","unstructured":"Pavelka K, Kivitz AJ, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, et al. Secukinumab 150\/300 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 3-year results from the phase 3 MEASURE 3 study. ACR Open Rheumatol. 2020;2(2):119\u201327.","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"3051_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.41477","volume":"73","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Blanco R, Dokoupilova E, Hall S, Kameda H, Kivitz AJ, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 2021;73(1):110\u201320.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"3051_CR15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/rheumatology\/key128","volume":"58","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Braun J, Deodhar A, Baraliakos X, Landewe R, Richards HB, et al. Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. Rheumatology (Oxford). 2019;58(3):388\u2013400.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3051_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/ard.2004.020503","volume":"64","author":"MC Creemers","year":"2005","unstructured":"Creemers MC, Franssen MJ, van\u2019t Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005;64(1):127\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3051_CR17","first-page":"862","volume":"34","author":"C Lukas","year":"2007","unstructured":"Lukas C, Braun J, van der Heijde D, Hermann KG, Rudwaleit M, Ostergaard M, et al. Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. J Rheumatol. 2007;34(4):862\u201370.","journal-title":"J Rheumatol"},{"issue":"6","key":"3051_CR18","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1136\/annrheumdis-2012-202939","volume":"73","author":"V Navarro-Compan","year":"2014","unstructured":"Navarro-Compan V, van der Heijde D, Ahmad HA, Miller CG, Wolterbeek R, Landewe R. Measurement error in the assessment of radiographic progression in rheumatoid arthritis (RA) clinical trials: the smallest detectable change (SDC) revisited. Ann Rheum Dis. 2014;73(6):1067\u201370.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3051_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3899\/jrheum.161232","volume":"44","author":"D Poddubnyy","year":"2017","unstructured":"Poddubnyy D. Radiographic evaluation of sacroiliac joints in axial spondyloarthritis - still worth performing? J Rheumatol. 2017;44(1):1\u20133.","journal-title":"J Rheumatol"},{"issue":"2","key":"3051_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40744-019-0146-6","volume":"6","author":"PC Robinson","year":"2019","unstructured":"Robinson PC, Sengupta R, Siebert S. Non-radiographic axial spondyloarthritis (nr-axSpA): advances in classification, imaging and therapy. Rheumatol Ther. 2019;6(2):165\u201377.","journal-title":"Rheumatol Ther"},{"issue":"6","key":"3051_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1136\/ard.62.6.519","volume":"62","author":"A van Tubergen","year":"2003","unstructured":"van Tubergen A, Heuft-Dorenbosch L, Schulpen G, Landewe R, Wijers R, van der Heijde D, et al. Radiographic assessment of sacroiliitis by radiologists and rheumatologists: does training improve quality? Ann Rheum Dis. 2003;62(6):519\u201325.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3051_CR22","doi-asserted-by":"publisher","first-page":"e000848","DOI":"10.1136\/rmdopen-2018-000848","volume":"5","author":"A Sepriano","year":"2019","unstructured":"Sepriano A, Ramiro S, Landewe R, Dougados M, van der Heijde D. Percentage of progressors in imaging: can we ignore regressors? RMD Open. 2019;5(1):e000848.","journal-title":"RMD Open"},{"issue":"5","key":"3051_CR23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/annrheumdis-2017-212377","volume":"77","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Baraliakos X, Hermann KA, Landewe RBM, Machado PM, Maksymowych WP, et al. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann Rheum Dis. 2018;77(5):699\u2013705.","journal-title":"Ann Rheum Dis"},{"key":"3051_CR24","doi-asserted-by":"crossref","unstructured":"Fernandez-Carballido C, Tornero C, Castro-Villegas MC, Galindez E, Garcia-Llorente JF, Garcia-Vivar ML, et al. No radiographic sacroiliitis progression was observed in patients with early spondyloarthritis at 6 years: results of the Esperanza multicentric prospective cohort. RMD Open. 2020;6(2):e001345.","DOI":"10.1136\/rmdopen-2020-001345"},{"issue":"11","key":"3051_CR25","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1136\/annrheumdis-2017-211596","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, Sepriano A, Molto A, van Lunteren M, Ramiro S, de Hooge M, et al. Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort. Ann Rheum Dis. 2017;76(11):1823\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3051_CR26","doi-asserted-by":"publisher","first-page":"e0230268","DOI":"10.1371\/journal.pone.0230268","volume":"15","author":"M Hebeisen","year":"2020","unstructured":"Hebeisen M, Micheroli R, Scherer A, Baraliakos X, de Hooge M, van der Heijde D, et al. Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: data from the Swiss Clinical Quality Management cohort. PLoS ONE. 2020;15(3):e0230268.","journal-title":"PLoS ONE"},{"issue":"12","key":"3051_CR27","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1002\/acr.23796","volume":"71","author":"S Ramiro","year":"2019","unstructured":"Ramiro S, van der Heijde D, Sepriano A, van Lunteren M, Molto A, Feydy A, et al. Spinal radiographic progression in early axial spondyloarthritis: five-year results from the DESIR cohort. Arthritis Care Res (Hoboken). 2019;71(12):1678\u201384.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"3051_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jbspin.2019.04.006","volume":"87","author":"K Aouad","year":"2020","unstructured":"Aouad K, Ziade N, Baraliakos X. Structural progression in axial spondyloarthritis. Joint Bone Spine. 2020;87(2):131\u20136.","journal-title":"Joint Bone Spine"},{"issue":"5","key":"3051_CR29","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/art.33465","volume":"64","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 2012;64(5):1388\u201398.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"3051_CR30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/BOR.0000000000000179","volume":"27","author":"S Tan","year":"2015","unstructured":"Tan S, Wang R, Ward MM. Syndesmophyte growth in ankylosing spondylitis. Curr Opin Rheumatol. 2015;27(4):326\u201332.","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"3051_CR31","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1136\/annrheumdis-2012-203075","volume":"73","author":"J Braun","year":"2014","unstructured":"Braun J, Baraliakos X, Hermann KG, Deodhar A, van der Heijde D, Inman R, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis. 2014;73(6):1107\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3051_CR32","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1093\/rheumatology\/kez025","volume":"58","author":"J Rademacher","year":"2019","unstructured":"Rademacher J, Tietz LM, Le L, Hartl A, Hermann KA, Sieper J, et al. Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis. Rheumatology (Oxford). 2019;58(9):1556\u201364.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"3051_CR33","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1136\/annrheumdis-2011-200411","volume":"71","author":"A van Tubergen","year":"2012","unstructured":"van Tubergen A, Ramiro S, van der Heijde D, Dougados M, Mielants H, Landewe R. Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. Ann Rheum Dis. 2012;71(4):518\u201323.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3051_CR34","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13075-018-1665-1","volume":"20","author":"A Deminger","year":"2018","unstructured":"Deminger A, Klingberg E, Geijer M, Gothlin J, Hedberg M, Rehnberg E, et al. A five-year prospective study of spinal radiographic progression and its predictors in men and women with ankylosing spondylitis. Arthritis Res Ther. 2018;20(1):162.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3051_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3899\/jrheum.160079","volume":"44","author":"AA Christiansen","year":"2017","unstructured":"Christiansen AA, Hendricks O, Kuettel D, Horslev-Petersen K, Jurik AG, Nielsen S, et al. Limited reliability of radiographic assessment of sacroiliac joints in patients with suspected early spondyloarthritis. J Rheumatol. 2017;44(1):70\u20137.","journal-title":"J Rheumatol"},{"issue":"5","key":"3051_CR36","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/annrheumdis-2015-208852","volume":"75","author":"A Deodhar","year":"2016","unstructured":"Deodhar A, Strand V, Kay J, Braun J. The term \u2018non-radiographic axial spondyloarthritis\u2019 is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis. 2016;75(5):791\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3051_CR37","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/ard.2010.145995","volume":"70","author":"D Poddubnyy","year":"2011","unstructured":"Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(8):1369\u201374.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3051_CR38","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1002\/art.38738","volume":"66","author":"R van den Berg","year":"2014","unstructured":"van den Berg R, Lenczner G, Feydy A, van der Heijde D, Reijnierse M, Saraux A, et al. Agreement between clinical practice and trained central reading in reading of sacroiliac joints on plain pelvic radiographs. Results from the DESIR cohort. Arthritis Rheumatol. 2014;66(9):2403\u201311.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3051_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13075-021-02428-8","volume":"23","author":"WP Maksymowych","year":"2021","unstructured":"Maksymowych WP, Claudepierre P, de Hooge M, Lambert RG, Landewe R, Molto A, et al. Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR. Arthritis Res Ther. 2021;23(1):43.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"3051_CR40","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1093\/rheumatology\/keab543","volume":"61","author":"WP Maksymowych","year":"2022","unstructured":"Maksymowych WP, Ostergaard M, Landewe R, Barchuk W, Liu K, Tasset C, et al. Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial). Rheumatology (Oxford). 2022;61(5):2063\u201371.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3051_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/annrheumdis-2021-221406","volume":"81","author":"J Braun","year":"2022","unstructured":"Braun J, Kiltz U, Baraliakos X. Significance of structural changes in the sacroiliac joints of patients with axial spondyloarthritis detected by MRI related to patients symptoms and functioning. Ann Rheum Dis. 2022;81(1):11\u20134.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03051-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03051-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03051-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:06:34Z","timestamp":1684195594000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03051-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3051"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03051-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]},"assertion":[{"value":"30 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review boards or independent ethics committees at each participating center. Written informed consent was obtained from all enrolled patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JB: Grant\/research support from: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB, Eli Lilly consultant for: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB, Eli Lilly and received speakers bureau fees from: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Medac, MSD (Schering-Plough), Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB pharma, Eli Lilly.RB: Research grants - AbbVie, MSD, and Roche; consulting fees - AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, UCB pharma and MSD; Speaker's bureau - AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, UCB pharma and MSD and Lilly.HMO: research funds from Janssen, Novartis, UCB and consulting and speaking fees from AbbVie, Celgene, Janssen, Eli Lilly and Company, MoonLake, Novartis, Pfizer, Takeda, and UCB. Supported by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC).LSG: grant\/research support from UCB, and consulting fees from AbbVie, Acelyrin, Gilead, Eli Lilly, Fresenius Kabi, Janssen, MoonLake, Novartis, Pfizer and UCB.FVB: reports research grants, consultancy fees or speaker honoraria from AbbVie, BMS, Amgen, Galapagos, Janssen, Eli Lilly, Merck, MoonLake, Novartis, Pfizer and UCB.SH: consulting fees, speaking fees, and\/or honoraria from Novartis, Merck, Janssen, Pfizer, Eli Lilly, and UCB and research support from AbbVie, UCB, Janssen, and Merck.HK: Grant\/research support from: Abbvie, Asahi-Kasei, Boehringer, Chugai, Eisai, Mitsubishi-Tanabe and Taisho, consultant for: Abbvie, Astellas, Boehringer, Eli Lilly, Gilead Sciences, Janssen, Medac, Novartis, Sanofi, Taisho, UCB, and received speaker bureau fees from: Abbvie, Asahi-Kasei, Astellas, BMS, Chugai, Eisai, Eli Lilly, Gilead Sciences, Janssen, Mitsubishi-Tanabe, Novartis and Pfizer.DP: Research grant from AbbVie, Eli Lilly, MSD, Novartis, Pfizer, Consultation fees from AbbVie, Biocad, BMS, Eli Lilly, Gilead, MSD, Novartis, Pfizer, Samsung Bioepis, UCB, Speaker fees from, AbbVie, BMS, Lilly, MSD, Novartis, Pfizer, UCB.MVS: Grant\/research support from: Novartis, Eli Lilly, Janssen, UCB Consultant fee: Abbvie, Novartis, Eli Lily, UCB; Speaker fee: Novartis, UCB, Janssen.DVH: Personal fees from Novartis, AbbVie, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Pfizer, UCB Pharma, and Director of Imaging Rheumatology bv.TZ: Employee of Novartis and owns Novartis stock.AS: Employee of Novartis and owns Novartis stock.AR: Employee of Novartis and owns Novartis stock.HBR: Employee of Novartis and owns Novartis stock.AD: Grant\/research support from: AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, GSK, Janssen, Novartis, Pfizer, and UCB, Consultant for AbbVie, Amgen, Aurinia, Bristol-Myers Squibb, Celgene, Eli Lilly, GSK, Janssen, Moonlake, Novartis, Pfizer, and UCB, speaking for AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}